Quantinno Capital Management LP Boosts Holdings in Exelixis, Inc. $EXEL

Quantinno Capital Management LP boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 44.3% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 115,592 shares of the biotechnology company's stock after purchasing an additional 35,498 shares during the period. Quantinno Capital Management LP's holdings in Exelixis were worth $4,958,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Motiv8 Investments LLC acquired a new stake in Exelixis during the fourth quarter worth about $26,000. Cassaday & Co Wealth Management LLC purchased a new position in Exelixis during the first quarter valued at approximately $27,000. Acumen Wealth Advisors LLC acquired a new position in Exelixis in the fourth quarter valued at approximately $29,000. Activest Wealth Management acquired a new position in Exelixis in the fourth quarter valued at approximately $32,000. Finally, Northwestern Mutual Wealth Management Co. boosted its position in Exelixis by 1,380.4% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 773 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Analyst Ratings Changes

EXEL has been the topic of a number of analyst reports. Weiss Ratings cut shares of Exelixis from a "buy (b+)" rating to a "buy (b)" rating in a research note on Friday, July 24th. Leerink Partners downgraded shares of Exelixis from an "outperform" rating to a "market perform" rating and set a $52.00 price target on the stock. in a report on Thursday. UBS Group set a $55.00 price target on shares of Exelixis in a research report on Monday. Morgan Stanley lifted their price objective on shares of Exelixis from $50.00 to $53.00 and gave the company an "equal weight" rating in a report on Thursday, July 23rd. Finally, Truist Financial decreased their price objective on shares of Exelixis from $56.00 to $52.00 and set a "hold" rating for the company in a research report on Thursday. Seven analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $49.79.

Insider Activity

In related news, Director Jack L. Wyszomierski sold 3,925 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $50.55, for a total value of $198,408.75. Following the completion of the transaction, the director directly owned 284,384 shares of the company's stock, valued at approximately $14,375,611.20. This represents a 1.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sue Gail Eckhardt sold 9,812 shares of the firm's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $50.14, for a total value of $491,973.68. Following the completion of the transaction, the director owned 16,079 shares in the company, valued at $806,201.06. The trade was a 37.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 130,824 shares of company stock valued at $6,555,231 in the last three months. Company insiders own 2.60% of the company's stock.

Key Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Exelixis reported second-quarter adjusted earnings of $0.91 per share, above the roughly $0.85–$0.86 analyst consensus and up from $0.75 a year earlier. Revenue increased 10.6% year over year to $628.7 million, while management highlighted continued execution and progress across its commercial and clinical pipeline. Exelixis Second-Quarter Results
• Positive Sentiment: The company launched a new Phase 3 colorectal cancer study targeting patients with residual disease after surgery. The trial expands the potential market for Exelixis’s pipeline and supports the longer-term growth case for its oncology portfolio. Phase 3 Colorectal Cancer Trial
• Neutral Sentiment: TD Cowen reaffirmed its Buy rating and maintained a $55 price target, citing the resilience of cabozantinib, cost discipline and potential upside from zanzalintinib, while acknowledging the near-term NET guidance reduction. TD Cowen Rating
• Negative Sentiment: Exelixis reduced its 2026 revenue outlook to $2.5 billion–$2.6 billion, below the approximately $2.6 billion consensus, with the midpoint cut by $50 million. The revenue miss and slower-than-expected NET launch raised concerns about near-term growth and prompted reports of lower 2026–2028 earnings expectations. Zacks Earnings and Outlook Report
• Negative Sentiment: Leerink Partners downgraded EXEL from Outperform to Market Perform with a $52 price target, while Zacks Research cut its rating to Strong Sell. Stifel raised its target to $51 but retained a Hold rating, indicating limited perceived upside at current levels.

Exelixis Trading Down 7.9%

NASDAQ:EXEL opened at $52.20 on Friday. Exelixis, Inc. has a 12 month low of $33.76 and a 12 month high of $57.57. The stock has a 50 day moving average of $54.10 and a two-hundred day moving average of $47.90. The firm has a market cap of $13.12 billion, a P/E ratio of 16.42, a price-to-earnings-growth ratio of 1.64 and a beta of 0.44.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.06. The business had revenue of $628.69 million during the quarter, compared to analysts' expectations of $636.40 million. Exelixis had a return on equity of 40.94% and a net margin of 35.33%.The business's revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.75 earnings per share. On average, research analysts forecast that Exelixis, Inc. will post 3.15 earnings per share for the current year.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source